Page 5 - புதியது மெக்ஸிகோ ஆரோக்கியம் அறிவியல் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from புதியது மெக்ஸிகோ ஆரோக்கியம் அறிவியல் மையம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In புதியது மெக்ஸிகோ ஆரோக்கியம் அறிவியல் மையம் Today - Breaking & Trending Today

'Grave risk:' Advocates say inmates should get speedy access to COVID-19 vaccine | iNFOnews


Lauren Krugel
A bin of COVID-19 syringes for the first round of health-care workers to be vaccinated at the University of New Mexico Health Sciences Center is seen in Albuquerque, N.M., on Dec. 16, 2020. Advocates say inmates should have speedy access to the COVID-19 vaccine, given how susceptible prisons and jails have been to outbreaks and how prevalent chronic disease is in that population. THE CANADIAN PRESS/AP-HO, UNM Health
December 30, 2020 - 4:00 PM
Advocates say inmates should have speedy access to the COVID-19 vaccine, given how susceptible prisons and jails have been to outbreaks and how prevalent chronic disease is in that population. ....

Prince Albert , United States , United Kingdom , Stony Mountain , New Brunswick , Jared Polis , Shawn Jeffords , Lauren Krugel , Deena Hinshaw , Catherine Latimer , Martha Paynter , Kerry Bowman , Fakiha Baig , Paul Merriman , Saskatchewan Health , Stony Mountain Institution , Dalhousie University , Ontario Ministry Of The Solicitor , Correctional Service Of Canada , John Howard Society Of Canada , University Of Toronto , University Of British Columbia , Winnipeg Regional Health Authority , University Of New Mexico Health Sciences Center , Joyceville Institution , National Advisory Committee On Immunizations ,

One Dose HPV Vaccine As Effective As Three-Dose Schedules Against Cervical Cancers


A single dose of the bivalent human papillomavirus (HPV) vaccine (Cervarix) offers a similar level of protection against the HPV-16/18 infections - which cause about 70% of cervical cancers - as current two- and three-dose schedules, according to data from two large phase 3 trials.
Worldwide, cervical cancer is the fourth most common cancer in women. The bivalent vaccine targets HPV types 16 and 18 that are responsible for about 70% of cervical cancers. The HPV-16/18 vaccine was initially approved to be given in three doses over 6 months, but many countries are moving to a two-dose schedule in adolescents.
This new combined analysis of two independent trials strengthens previous findings from the NCI Costa Rica HPV Vaccine Trial (CVT) which reported that young women who received three, two, or one dose of the bivalent vaccine were equally protected against infection with HPV-16/18 for at least 4 years after vaccination. ....

United States , Costa Rica , Ministry Of Health Costa Rica , National Cancer Institute , University Of New Mexico Health Sciences Center , National Institutes Of Health , Us National Cancer Institute , National Institutes , Papilloma Trial , Young Adults , Latin America , Cosette Wheeler , New Mexico Health Sciences Center , Cancer Institute , Health Office , Glaxosmithkline Biologicals , ஒன்றுபட்டது மாநிலங்களில் , கோஸ்டா ரிக்கா , அமைச்சகம் ஆஃப் ஆரோக்கியம் கோஸ்டா ரிக்கா , தேசிய புற்றுநோய் நிறுவனம் , பல்கலைக்கழகம் ஆஃப் புதியது மெக்ஸிகோ ஆரோக்கியம் அறிவியல் மையம் , தேசிய நிறுவனங்கள் ஆஃப் ஆரோக்கியம் , எங்களுக்கு தேசிய புற்றுநோய் நிறுவனம் , தேசிய நிறுவனங்கள் , லத்தீன் அமெரிக்கா , காசெட்டே சக்கர வாகனம் ,